SF Healthcare Week: The CEO of Akeso talks about its PD1xVEGF, other bi-specific targets, and her opinion of China's position in the global biotech ecosystem

blonca9
Jan 14
1 min read

Chairman & CEO Michelle Xia describes the clinical trial that was run comparing the company's PD1xVEGF vs Akeso, development plans outside of lung cancer, other targets (including PD1xCTLA4), and her opinion of the innovation coming out of China.

Recent Posts

See All

The CEO of Tennr, which raised a $101M series C earlier this summer, explains how the company's platform uses large language models to make the patient referral process to specialists more efficient

After exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

SF Healthcare Week: The CEO of Akeso talks about its PD1xVEGF, other bi-specific targets, and her opinion of China's position in the global biotech ecosystem

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight